Getting older motivated Alfred Belle of Hawthorne to lose weight that led him to be crowned king of a weight loss program.

And when filmmakers aren’t sanitizing the experience or staying within the boundaries of mainstream acceptability, you get an ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight loss like Ozempic. Here's the deal.

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year or so.

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average of 27.3 pounds in the first of two pivotal trials, queuing up plans ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it may not be as potent as injectable GLP-1 drugs on the market.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Eli Lilly, makers of weight loss injection Zepbound, could soon be making its GLP-1 drug in pill form.

Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.